Key clinical point: Both trazodone OAD (once-a-day) and venlafaxine XR (extended-release) are effective antidepressants for the treatment of the moderate-to-severe major depressive disorder (MDD).
Major finding: Both treatments demonstrated good efficacy in terms of reduction in the 17-item Hamilton Depression Rating Scale (HAM-D-17) total score at week 8 vs. baseline (intent-to-treat: trazodone, –12.9; venlafaxine, –14.7; per protocol: trazodone, –15.4; venlafaxine, –16.4). A significant difference in favor of venlafaxine XR was observed after 8 weeks. Mean HAM-D-17 reduction was significantly higher in the trazodone OAD group after only 7 days of treatment (P less than .05). The most common adverse events were dizziness and somnolence in the trazodone group and nausea and headache in the venlafaxine group.
Study details: 324 patients were randomly assigned to trazodone OAD (n=166) and venlafaxine XR (n=158) groups.
Disclosures: This study was sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A., Italy. The lead author had been a consultant and/or a speaker and/or has received research grants from Allergan, Angelini, Aspen, Boehringer Ingelheim, Doc Generici, FB-Health, Italfarmaco, Janssen, Lundbeck, Mylan, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, Vifor.
Fagiolini A et al. Int Clin Psychopharmacol. 2020 Jan 15. doi: 10.1097/YIC.0000000000000304.